Non–Small Cell Lung Cancer, Version 4.2024
Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Douglas E. Wood(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David S. Ettinger(Sidney Kimmel Comprehensive Cancer Center), Dara L. Aisner(University of Colorado Cancer Center), Wallace Akerley(University of Utah), Jessica R. Bauman(Fox Chase Cancer Center), Ankit Bharat(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Débora S. Bruno(Cleveland Clinic), Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Lucian R. Chirieac(Dana-Farber Brigham Cancer Center), Malcolm M. DeCamp(University of Wisconsin Carbone Cancer Center), Aakash Desai(University of Colorado Cancer Center), Thomas J. Dilling(Moffitt Cancer Center), Jonathan E. Dowell(Southwestern Medical Center), Gregory A. Durm(Indiana University Melvin and Bren Simon Comprehensive Cancer Center), Scott Gettinger(Yale Cancer Center), Travis E. Grotz(WinnMed), Matthew A. Gubens(UCSF Helen Diller Family Comprehensive Cancer Center), Aditya Juloori(University of Chicago Medicine Comprehensive Cancer Center), Rudy P. Lackner(Susan Thompson Buffett Foundation), Michael Lanuti(Massachusetts General Hospital), Jules Lin(University of Michigan), Billy W. Loo(Cancer Institute (WIA)), Christine M. Lovly(Breast Cancer Research Foundation), Fabien Maldonado(Breast Cancer Research Foundation), Erminia Massarelli(City Of Hope National Medical Center), Daniel Morgensztern(Barnes-Jewish Hospital), Trey C. Mullikin(Cancer Institute (WIA)), Thomas Ng(University of Tennessee Health Science Center), Dawn Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Dwight H. Owen(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sandip Pravin Patel(UC San Diego Health System), Tejas Patil(Sidney Kimmel Comprehensive Cancer Center), Patricio M. Polanco(Southwestern Medical Center), Jonathan W. Riess(UC Davis Comprehensive Cancer Center), Theresa A. Shapiro(Sidney Kimmel Comprehensive Cancer Center), Aditi P. Singh(University of Pennsylvania), James Stevenson(Cleveland Clinic), Alda L. Tam(The University of Texas MD Anderson Cancer Center), Tawee Tanvetyanon(Moffitt Cancer Center), Jane Yanagawa(University of Colorado Cancer Center), Stephen C. Yang(Sidney Kimmel Comprehensive Cancer Center), Edwin Yau(Roswell Park Comprehensive Cancer Center), Kristina M. Gregory(National Comprehensive Cancer Network), Lisa Hang(National Comprehensive Cancer Network)
Cited by 724
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.
Related Papers
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist, Belinda A. Waltman, Dora Dias‐Santagata et al.|Science Translational Medicine|2011|3.6k